Arundhathi Arivajiagane, Chuang Wen-Han, Chen Jen-Kun, Wang Shin-E, Shyr Yi-Ming, Chen Jiun-Yu, Liao Wei-Neng, Chen Hsin-Wei, Teng Yi-Min, Pai Chiao-Chih, Wang Chih-Hong
Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan.
Institute of Biomedical Engineering & Nanomedicine, National Health Research Institutes, Miaoli, Taiwan.
Oncotarget. 2016 Jul 13;7(34):55437-55448. doi: 10.18632/oncotarget.10583. eCollection 2016 Aug 23.
Recent studies have implicated the prorenin receptor (PRR) is associated with pancreatic tumorigenesis. We therefore investigated the role of PRR in pancreatic tumorigenesis and assessed whether PRR can serve as a target for imaging diagnosis at early stages of PDAC. Here we show that aberrant expression of PRR in premalignant PanIN lesions, and human PDAC samples, and PDAC cell lines, particularly in Panc-1 cells. Interestingly, PRR expression was positively associated with PDAC progression. Moreover, overexpression of human PRR resulted in increased cell proliferation and decreased apoptosis, while knockdown of human PRR caused decreased cell proliferation and enhanced apoptosis in pancreatic cancer cells. We also observed that overexpression of human PRR enhanced MAPK and PI3K/Akt signaling pathways in PDAC cells, while knockdown of human PRR suppressed both of pathways. The confocal imaging analysis showed that human PRR was highly expressed in Panc-1, ASPC, and Miapaca cells, whereas BXPC-3, and HPAC cells had a significantly lower fluorescent signals. Consistently, the single-photon emission computed tomography (SPET/CT) showed that the uptake of anti-PRR labelled with I was higher in Panc-1 and ASPC tumors-bearing mice after 96 hours injection. Importantly, tumors in pancreas of mice had a significant increased PRR expression and accumulation of radioactivity at 96 h after injection. These data suggest that I-anti-PRR can detect the orthotopic tumors in mice. Therefore, anti-PRR labelled with I is a promising radiotracer for imaging diagnosis at early stages of pancreatic cancer.
最近的研究表明,肾素原受体(PRR)与胰腺肿瘤发生有关。因此,我们研究了PRR在胰腺肿瘤发生中的作用,并评估PRR是否可作为胰腺癌(PDAC)早期成像诊断的靶点。在此我们表明,PRR在癌前胰腺上皮内瘤变(PanIN)病变、人PDAC样本及PDAC细胞系中存在异常表达,尤其是在Panc-1细胞中。有趣的是,PRR表达与PDAC进展呈正相关。此外,人PRR的过表达导致细胞增殖增加和凋亡减少,而人PRR的敲低则导致胰腺癌细胞增殖减少和凋亡增强。我们还观察到,人PRR的过表达增强了PDAC细胞中的MAPK和PI3K/Akt信号通路,而人PRR的敲低则抑制了这两条通路。共聚焦成像分析显示,人PRR在Panc-1、ASPC和Miapaca细胞中高表达,而BXPC-3和HPAC细胞的荧光信号明显较低。同样,单光子发射计算机断层扫描(SPET/CT)显示,注射96小时后,用I标记的抗PRR在荷Panc-1和ASPC肿瘤的小鼠中的摄取更高。重要的是,注射96小时后,小鼠胰腺中的肿瘤PRR表达和放射性积累显著增加。这些数据表明,I-抗PRR可检测小鼠原位肿瘤。因此,用I标记的抗PRR是一种有前景的放射性示踪剂,可用于胰腺癌早期成像诊断。